Results
|
|
41.
|
|
|
|
42.
|
|
|
|
43.
|
|
|
|
44.
|
|
|
|
45.
|
|
|
|
46.
|
|
|
|
47.
|
|
|
|
48.
|
|
|
|
49.
|
|
|
|
50.
|
|
|
|
51.
|
|
|
|
52.
|
|
|
|
53.
|
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. [electronic resource] by
- Powles, Ryan L
- Redmond, David
- Sotiriou, Christos
- Loi, Sherene
- Fumagalli, Debora
- Nuciforo, Paolo
- Harbeck, Nadia
- de Azambuja, Evandro
- Sarp, Severine
- Di Cosimo, Serena
- Huober, Jens
- Baselga, Jose
- Piccart-Gebhart, Martine
- Elemento, Olivier
- Pusztai, Lajos
- Hatzis, Christos
Producer: 20191009
In:
JAMA oncology vol. 4
Availability: No items available.
|
|
|
54.
|
Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. [electronic resource] by
- Takahashi, F
- Chiba, N
- Tajima, K
- Hayashida, T
- Shimada, T
- Takahashi, M
- Moriyama, H
- Brachtel, E
- Edelman, E J
- Ramaswamy, S
- Maheswaran, S
Producer: 20110915
In:
Oncogene vol. 30
Availability: No items available.
|
|
|
55.
|
|
|
|
56.
|
|
|
|
57.
|
|
|
|
58.
|
|
|
|
59.
|
|
|
|
60.
|
|